AGTR1 and glioblastoma: In GBM cells, we showed that this (Q-L) hybrid retains the binding potential of losartan to the AT1R (Q-L IC50; 140 ± 10 nM, losartan IC50; 10.3 ± 1.1 nM) through competition-binding experiments and simultaneously exhibits ROS inhibition and antioxidant capacity similar to native quercetin.